Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456698 | 1.00 | POLB (0.31) | POLBCYP2C19 | |
| SCHEMBL2353469 | 1.00 | POLB (0.31) | POLBCYP2C19 | |
| Hydrochloric Acid SCHEMBL11816180 | 0.98 | POLB (0.30) | POLBCYP2C19 | |
| Hydrochloric Acid SCHEMBL11816174 | 0.98 | POLB (0.30) | POLBCYP2C19 | |
| SCHEMBL8071026 | 0.74 | — | — | |
| SCHEMBL311601 | 0.72 | — | — | |
| SCHEMBL4343624 | 0.72 | — | — | |
| SCHEMBL11665315 | 0.67 | — | — | |
| SCHEMBL2541407 | 0.64 | — | — | |
| SCHEMBL11103519 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0615855-B1 | Recording sheets containing pyridinium and/or piperazinum compounds | XEROX CORP (US) | 1997-05-14 | — | — | EP | claimed |
| US-3962447-A | Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and method of using same | INTERX RESEARCH CORPORATION (US) | 1976-06-08 | — | — | US | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240299680-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-09-12 | — | — | US | disclosed |
| US-12005185-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2023114462-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230191047-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4171542-A1 | METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING | Lachesis Biosciences Limited (AU) | 2023-05-03 | — | — | EP | disclosed |
| US-20110230473-A1 | Methods and Compositions for Treating Status Epilepticus and Seizures Causing Status Epilepticus | GORDON RICHARD K | 2011-09-22 | — | — | US | disclosed |
| EP-2355818-A2 | METHODS AND COMPOSITIONS FOR TREATING STATUS EPILEPTICUS AND SEIZURES CAUSING STATUS EPILEPTICUS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010042780-A2 | METHODS AND COMPOSITIONS FOR TREATING STATUS EPILEPTICUS AND SEIZURES CAUSING STATUS EPILEPTICUS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2010-04-15 | — | — | WO | disclosed |
| US-3962447-A | Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and method of using same | INTERX RESEARCH CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | POLB 4422/4885CYP2C19 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.